Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Melvin Heyman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics. Authored (or co-authored) 312 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT02403323
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated